Lexicon Pharmaceuticals (LXRX) Enterprise Value (2023 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed Enterprise Value for 6 consecutive years, with -$96.2 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 59.56% to -$96.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$96.2 million, a 59.56% increase, with the full-year FY2025 number at -$96.2 million, up 59.56% from a year prior.
- Enterprise Value was -$96.2 million for Q4 2025 at Lexicon Pharmaceuticals, up from -$116.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$96.2 million in Q4 2025 to a low of -$355.6 million in Q1 2024.
- A 3-year average of -$204.9 million and a median of -$206.6 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: crashed 235.67% in 2024, then soared 59.56% in 2025.
- Lexicon Pharmaceuticals' Enterprise Value stood at -$170.0 million in 2023, then plummeted by 39.95% to -$238.0 million in 2024, then skyrocketed by 59.56% to -$96.2 million in 2025.
- Per Business Quant, the three most recent readings for LXRX's Enterprise Value are -$96.2 million (Q4 2025), -$116.0 million (Q3 2025), and -$139.0 million (Q2 2025).